Search clinical trials for: Hemophilia B

Total 489525 results

Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors (HAVEN 3)

Hemophilia A

Australia, Taiwan, Korea, Republic of, France, Germany, Italy, South Africa, Spain, United States, Japan, Ireland, Poland, United Kingdom, Costa Rica
Freeline Therapeutics

Completed

AAV Gene Therapy Screening/Observational Protocol (ECLIPSE) (ECLIPSE)

Hemophilia B | Blood Coagulation Disorders, Inherited | Blood Coagulation Disorder | Haematologic Disease

United States, United Kingdom, Australia, Netherlands, Austria, France, Ireland, Italy, Turkey, Canada, Germany, South Africa
University Hospital, Geneva
Swiss Hemophilia Network

Completed

Pregnancy and Fibrinogen Disorders (FIBRINOGEST)

Hypofibrinogenemia, Congenital | Afibrinogenemia, Congenital | Dysfibrinogenemia, Congenital

Switzerland, France, Slovakia
Tremeau Pharmceuticals, Inc.

Terminated

Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy (RESET-HA)

Hemophilic Arthropathy

United States, Italy, Turkey, Spain, Australia, Canada, Ukraine, Poland
Cliniques universitaires Saint-Luc- Université...

Completed

Outcomes of Prophylaxis With Emicizumab in Children With Severe Hemophilia A in Ivory Coast

Hemophilia A

Côte D'Ivoire
University of Pennsylvania
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Brigham... and other collaborators

Completed

Gut Microbiome and p-Inulin in Hemodialysis

End-Stage Renal Disease | Gut Microbiome Dysbiosis

United States
Institute of Hematology & Blood Diseases Hospital
East China University of Science and Technology

Active, not recruiting

Gene Therapy for Chinese Hemophilia B

Hemophilia B

China
Investigación en Hemofilia y Fisioterapia

Active, not recruiting

Pain and Joint Status With Psychosocial Factors in Patients With Hemophilia

Hemophilia Arthropathy

Spain
AryoGen Pharmed Co.

Completed

Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

Iran, Islamic Republic of
Swedish Orphan Biovitrum
Kantar Health; Cerner Enviza (former Kantar Health)

Completed

Psychometric Validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST) (Hemo-FAST)

Hemophilia A | Hemophilia B

France
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

RIXUBIS PMS India (RIXUBIS PMS)

Hemophilia B

India
Bayer
American Thrombosis and Hemostasis Network

Terminated

Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry

Hemophilia A

United States
Cukurova University

Completed

Posture Analysis for Patients With Haemophilia

Hemophilia | Postural; Defect | Muscle Disorder

Turkey
Baxalta now part of Shire
Takeda

Completed

RIXUBIS Drug Use-Result Survey (Japan)

Hemophilia B

Japan
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice

Acquired Hemophilia A

United States, Italy, United Kingdom, Germany, Austria, Netherlands, France
Chulalongkorn University

Completed

Clinical Outcomes of Low Dose PK-guided EHL FVIII Concentrates Versus Standard Prophylaxis in Severe Haemophilia A

Severe Hemophilia A Without Inhibitor

Thailand
CSL Behring

Completed

A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

Hemophilia B

United States, Australia, Japan, France, Philippines, Spain, Czechia, Israel, Canada, Germany, Austria, Bulgaria, Italy, Malaysia, South Africa
Istanbul University - Cerrahpasa (IUC)

Completed

The Effects of Exercise Training in Children With Hemophilia

Hemophilia

Turkey
Pfizer

Terminated

A Study of Marstacimab to Compare Prefilled Pen (PFP) Device to Prefilled Syringe (PFS) Device

Healthy Volunteers

Belgium
Pfizer

Completed

Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia B

Hemophilia B

India
CSL Behring

Completed

Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B

Hemophilia B

Germany, Denmark, Netherlands
Washington Institute for Coagulation
Genentech, Inc.

Completed

Handheld Ultrasound (HHUS) for Home Use in Hemophilia (HHUS)

Hemophilia A | Joint Bleed

United States
Bloodworks
CSL Behring

Completed

Joint Health Study

Hemophilia B

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Study Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age

Hemophilia A
Grifols Biologicals, LLC

Completed

Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A

Severe Hemophilia A

Poland
Prof. Dr. Dr. Thomas Hilberg
Pfizer

Completed

iT-based Sports Therapy Application in Haemophilia (iT-BaSTAH)

Sports Physical Therapy | Haemophilia

Germany
Agios Pharmaceuticals, Inc.

Completed

A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)

Anemia, Hemolytic | Pyruvate Kinase Deficiency

United States, Spain, Switzerland, Turkey, Germany, France, United Kingdom, Japan, Netherlands, Brazil, Canada, Czechia, Denmark, Italy, Korea, Republic of, Thailand
Baxalta now part of Shire

Terminated

A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects

Hemophilia B

Turkey, Spain
Xperiome
The Touro College and University System

Withdrawn

Medication Adherence and Non-adherence in Adults With Rare Disease

Hemophilia A | Hemophilia B | Idiopathic Pulmonary Fibrosis | Myasthenia Gravis | Cystic Fibrosis | Sickle Cell Disease
Hoffmann-La Roche

Completed

An Observational Study to Evaluate Physical Activity, Bleeding Incidence and Health Related Quality of Life, in Participants With Haemophilia A Without Inhibitors Receiving Standard of Care Treatment (POWER)

Haemophilia A | Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor | Severe Hereditary Factor VIII Deficiency Disease Without Inhibitor

Italy
Swedish Orphan Biovitrum

Completed

A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B (PREVENT)

Haemophilia A | Haemophilia B

Germany
Bioverativ, a Sanofi company

Completed

A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)

Hemophilia A

United States, Japan
Bioverativ, a Sanofi company
Swedish Orphan Biovitrum

Completed

An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A

Hemophilia A

United States, France, Italy, Spain, Netherlands, United Kingdom, Ireland, New Zealand, Poland, Australia, Germany, Brazil, Sweden, Canada
Baylor College of Medicine
Shire

Active, not recruiting

Low VW Activity in Adolescent HMB (Low VWF)

Von Willebrand Factor Deficiency

United States
Octapharma

Terminated

Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A

Severe Hemophilia A

Bulgaria
Genzyme, a Sanofi Company

Completed

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors (ATLAS-INH)

Hemophilia A | Hemophilia B

United States, Australia, Canada, China, France, Korea, Republic of, Malaysia, Turkey, Ukraine, United Kingdom, Germany, India, Italy, Japan, South Africa, Spain, Taiwan
Genzyme, a Sanofi Company

Completed

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors

Hemophilia A | Hemophilia B

United States, Australia, China, Denmark, France, Israel, Japan, Korea, Republic of, Malaysia, Turkey, Ukraine, United Kingdom, Germany, India, South Africa, Spain, Taiwan, Hungary, Italy
Bioverativ, a Sanofi company
Swedish Orphan Biovitrum

Completed

A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)

Hemophilia A With Inhibitors

United States, Spain, Canada, Belgium, France, Bulgaria, Italy, United Kingdom, Japan, Germany
Bioverativ, a Sanofi company
Swedish Orphan Biovitrum

Completed

Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B (PUPs B-LONG)

Hemophilia B

United States, Italy, Ireland, New Zealand, United Kingdom, Australia, Netherlands, Denmark, Poland, Sweden, France
Sangamo Therapeutics

Terminated

Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B

Hemophilia B

United States
Dow University of Health Sciences

Completed

Effects of Progressive Resistance Training Compared With Aerobic Training in Patients With Hemophilia

Quality of Life | Muscle Weakness

Pakistan
Fondazione Angelo Bianchi Bonomi
Sintesi Research Srl

Active, not recruiting

Type 3 Von Willebrand International Registries Inhibitor Prospective Study (3WINTERSIPSEXT)

Type 3 Von Willebrand's Disease

Finland, France, Germany, Hungary, Iran, Islamic Republic of, Italy, Netherlands, Spain, Sweden, United Kingdom
Swedish Orphan Biovitrum
Bioverativ Therapeutics Inc.

Completed

Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies (ReITIrate)

Hemophilia A

Ireland, United Kingdom, Germany, United States, Canada, Slovenia, Sweden
Children's Hospital Los Angeles
Takeda

Active, not recruiting

A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab

Hemophilia A With Inhibitor

United States
Investigación en Hemofilia y Fisioterapia

Completed

Self-myofascial Release With Foam Roller in Patients With Hemophilic Knee Arthropathy

Haemophilia

Spain
Johns Hopkins All Children's Hospital
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT)

Venous Thrombosis

United States, Australia, Canada, Austria, Israel, Netherlands
Laboratoire français de Fractionnement et de Biotechnologies
LFB USA, Inc.

Completed

LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures (PerSept3)

Hemophilia

United States, Ukraine, Mexico, Russian Federation, South Africa, Spain
Laboratoire français de Fractionnement et de Biotechnologies
LFB USA, Inc.

Completed

A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (PERSEPT2)

Hemophilia A With Inhibitors | Hemophilia B With Inhibitors

Bulgaria, Ukraine, Czechia, United States, Georgia, South Africa
AryoGen Pharmed Co.

Completed

Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven

Factor VII Deficiency | Hemophilia A With Inhibitor | Hemophilia B With Inhibitor | Glanzmann's Thrombasthenia

Iran, Islamic Republic of
Children's Hospital Medical Center, Cincinnati
AstraZeneca

Completed

Benralizumab for Eosinophilic Gastritis (BEGS) (BEGS)

Eosinophilic Gastritis or Gastroenteritis

United States

Search clinical trials for: Hemophilia B

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations